What is the purpose of registration submission guide, based on data from scientific literature?
Publication of the Public Consultation for the review of RDC 200 - what is new?
NEW REGULATORY FRAMEWORK OF API
COVID-19: What facilities is ANVISA providing at this time of crisis?
Why are 24% of drug registrations still rejected?
API, BPF and drug dossier - How to align the processes to ensure success in registration?
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Publication of the new API regulatory framework: what is essential to know?
Outcome of the RDC 200 Review Working Group meeting - 02/05/20
Cannabis: the rules of the new regulation system.
Everything you need to know about the new rules for Drug Renewal.
API: Why control it?
CTD - Why?
Which points generate the most rejections and demands in innovative drug processes?
DDCM- What are the most demanding requirements by ANVISA?
Practical aspects of biosimilar registration
Comparability of biosimilars: unraveling this enigma
ANVISA’S new era: is the regulatory sector prepared for this?
